T
Tellus Therapeutics
Developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury
About Tellus Therapeutics
Tellus Therapeutics is a biopharmaceutical company focused on neonatal care, specifically on developing treatments for brain injury and demyelination in newborns. The company's lead product, TT-20, is designed to address diffuse white matter injury (DWMI) in premature infants by reversing the developmental arrest of oligodendrocyte progenitor cells (OPCs), which are crucial for myelination.
The company's business model is centered on the research and development of novel therapeutics to address unmet needs in neonatal care. Tellus Therapeutics was seeded by Xontogeny, a life sciences accelerator, and has successfully raised capital through seed and Series A financing rounds. The company collaborates with leading research institutions and leverages a management team with extensive experience in drug development and commercialization.
Tellus Therapeutics operates in the niche market of neonatal critical care, targeting a patient population with limited treatment options. The company's primary customers would be neonatal intensive care units (NICUs) and pediatric hospitals. The company is not yet generating revenue, as its products are still in the development phase. Future revenue will likely be generated through partnerships, licensing agreements, or the eventual sale of its approved therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Durham, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2022 | $35M | $140M | Xontogeny | ↗ |
| SEED✓Equity / VC | May 2021 | $2M | $8M | Xontogeny | — |
Growth signals
Latest recorded traffic for Tellus Therapeutics is 1.3K monthly website visits, up 71.1% over the last three months. Tellus Therapeutics's team declined 44.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Xontogeny
Other known investors2 additional known investors
Duke University
MassChallenge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tellus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tellus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.